Novo Nordisk CEO Mike Doustdar told Reuters that oral weight-loss pills could capture 50% of the obesity drug market by 2030, projected to reach $100-150 billion. The Danish drugmaker beat rival Eli Lilly to market with the first obesity pill in 2026. Oral Wegovy generated 5.5 billion Danish crowns ($843 million) in first-half 2026 sales and now accounts for over 80% of new US oral obesity prescriptions.
Oral obesity drug market forecast
- ▪Competitors' pipelines contain eight injectables for every two pills under development as of September 2026
- ▪Wall Street forecasts expect oral treatments to account for about 14% to 40% of the obesity market by 2030
- ▪Novo Nordisk CEO Mike Doustdar said weight-loss pills could capture as much as half of the global obesity drug market by 2030
Novo Nordisk pill pipeline
- ▪Novo Nordisk's oral obesity pipeline includes next-generation dual-acting tablet zenagamtide
- ▪Novo Nordisk has five oral obesity treatments in development as of September 2026
- ▪Novo Nordisk's oral obesity pipeline includes an oral amylin analogue
Novo market position reversal
- ▪Eli Lilly has overtaken Novo Nordisk's market share in the obesity drug market as of September 2026
- ▪Novo Nordisk held a Capital Markets Day in London on September 21, 2026
- ▪Novo Nordisk's 2021 launch of Wegovy weight-loss medication helped make Novo Nordisk Europe's most valuable listed company
- ▪Novo Nordisk beat rival Eli Lilly to market with the first obesity pill, oral Wegovy, in 2026
- ▪Novo Nordisk shares have tumbled more than 70% from their peak following Wegovy's 2021 launch as of September 2026
- ▪Maziar Mike Doustdar is CEO and president of Novo Nordisk as of September 2026
Oral Wegovy sales performance
- ▪Novo Nordisk captures more than 80% of new oral obesity prescriptions in the US as of September 2026
- ▪Oral therapies account for about a third of US obesity prescriptions following oral Wegovy's rollout as of September 2026
- ▪Novo Nordisk's Oral Wegovy generated nearly 5.5 billion Danish crowns ($843 million) in first-half 2026 sales
Patent protection strategy
- ▪Semaglutide, the active ingredient in Wegovy, loses exclusivity in the early 2030s
- ▪Oral Wegovy is protected from generic competition into the mid and late 2030s through patents covering its SNAC delivery technology
Debatable claims
- ▪The obesity drug market should prioritize oral medications over injectables
- ▪Patient preference genuinely drives the shift to oral obesity drugs
- ▪Novo Nordisk's SNAC delivery patents legitimately protect obesity pill innovation
Story comments
Loading comments…